Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by overthelakeonlyon Sep 16, 2015 10:19am

109 Views

Post# 24108344

RE:RE:RE:RE:Is it just me .......

To follow my explanation, if we have 60% and 40%, the absolute benefit is 20% and relative benefit is 33%. Everything over 15% absolute is very good. Xigris was approved by FDA but was withdrawn 10 years after and trial results were 6% absolute and 19% relative.

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025